Test na riziko cukrovky — Diabetes Risk Screen

Focused diabetes screening at SYNLAB Brno combining fasting glucose with glycated haemoglobin (HbA1c) — two complementary markers that together detect glucose metabolism disorders more reliably than either test alone. At 220 CZK (~9 EUR), an accessible screen for the most prevalent metabolic disease in the Czech Republic.

This panel pairs two complementary approaches to glucose metabolism assessment. Fasting plasma glucose delivers a point-in-time snapshot, with the World Health Organization diagnostic threshold set at 7.0 mmol/L (126 mg/dL) for diabetes and values between 5.6 and 6.9 mmol/L defining impaired fasting glucose (pre-diabetes). HbA1c quantifies the percentage of haemoglobin molecules that have undergone non-enzymatic glycation over the preceding 8-12 weeks, providing a time-averaged picture unaffected by meal timing or day-to-day glucose fluctuations. Both the WHO and the American Diabetes Association accept HbA1c at or above 6.5% (48 mmol/mol) as independently diagnostic of diabetes. The pre-diabetic range (5.7-6.4%, or 39-47 mmol/mol) identifies individuals at high risk of progression — the landmark Diabetes Prevention Program trial demonstrated that structured lifestyle intervention reduces this progression risk by 58%. Using both markers simultaneously improves diagnostic sensitivity beyond what either achieves alone. Approximately 30% of diabetes cases detected by HbA1c would be missed by fasting glucose, and the reverse is also true. Discordant results — one marker elevated, the other normal — can indicate early or atypical presentations that merit closer follow-up. For patients already living with diabetes, HbA1c is the standard monitoring tool. European guidelines generally target a value below 7.0% for most adults, with each 1% reduction associated with approximately 21% fewer diabetes-related complications. Type 2 diabetes prevalence in the Czech Republic is estimated at 8-9% of the adult population, with a further 15-20% in pre-diabetic states. The Moravian region mirrors the national pattern. Early detection through accessible self-pay screening is a cost-effective strategy both for the healthcare system and for individual patients who benefit from timely lifestyle modification. For visitors from Austria or Slovakia, where equivalent dual-marker diabetes screening costs 30-50 EUR, the 220 CZK (~9 EUR) Brno price is notably lower. The Titanium collection point is convenient for train arrivals. Blood draw and serum separation are included. Results within two business days.